[go: up one dir, main page]

WO2008114733A1 - 抗Claudin-4抗体 - Google Patents

抗Claudin-4抗体 Download PDF

Info

Publication number
WO2008114733A1
WO2008114733A1 PCT/JP2008/054769 JP2008054769W WO2008114733A1 WO 2008114733 A1 WO2008114733 A1 WO 2008114733A1 JP 2008054769 W JP2008054769 W JP 2008054769W WO 2008114733 A1 WO2008114733 A1 WO 2008114733A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cldn4
extracellular domain
fragment
claudin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/054769
Other languages
English (en)
French (fr)
Inventor
So Ohta
Hiroshi Ando
Masayo Suzuki
Shinobu Kawamoto
Mariko Nakano
Kazuyasu Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to JP2009505202A priority Critical patent/JPWO2008114733A1/ja
Priority to EP08722165A priority patent/EP2138576A4/en
Publication of WO2008114733A1 publication Critical patent/WO2008114733A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　本発明の目的は、Claudin-4（以下、CLDN4と表記する）遺伝子によりコードされるポリペプチドおよび/または、Claudin-3（以下、CLDN3と表記する）遺伝子によりコードされるポリペプチドが関与する疾患に対する治療薬及び診断に有用なモノクローナル抗体またはその使用方法を提供することにある。 　本発明は、CLDN4の細胞外領域の立体構造を特異的に認識し、かつ細胞外領域に結合するモノクローナル抗体または該抗体断片、CLDN4およびCLDN3の細胞外領域の立体構造を特異的に認識し、かつ該細胞外領域に結合するモノクローナル抗体または該抗体断片、該抗体を産生するハイブリドーマ、該抗体をコードするDNA、該DNAを含んでなるベクター、該ベクターを形質転換して得られる形質転換体、該ハイブリドーマまたは形質転換体を用いる抗体または抗体断片の製造方法、ならびに該抗体または抗体断片を用いるCLDN4および/またはCLDM3遺伝子によりコードされるポリペプチドが関与する疾患の診断薬または治療薬を提供する。
PCT/JP2008/054769 2007-03-16 2008-03-14 抗Claudin-4抗体 Ceased WO2008114733A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009505202A JPWO2008114733A1 (ja) 2007-03-16 2008-03-14 抗Ｃｌａｕｄｉｎ−４抗体
EP08722165A EP2138576A4 (en) 2007-03-16 2008-03-14 ANTI-CLAUDIN-4 ANTIBODY

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-068064 2007-03-16
JP2007068064 2007-03-16
JP2007223803 2007-08-30
JP2007-223803 2007-08-30

Publications (1)

Publication Number Publication Date
WO2008114733A1 true WO2008114733A1 (ja) 2008-09-25

Family

ID=39765841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/054769 Ceased WO2008114733A1 (ja) 2007-03-16 2008-03-14 抗Claudin-4抗体

Country Status (4)

Country Link
US (1) US8076458B2 (ja)
EP (1) EP2138576A4 (ja)
JP (1) JPWO2008114733A1 (ja)
WO (1) WO2008114733A1 (ja)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
WO2014132647A1 (ja) * 2013-03-01 2014-09-04 公益財団法人ヒューマンサイエンス振興財団 抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー
US9321842B2 (en) 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
US9487584B2 (en) 2009-11-11 2016-11-08 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
CN106459165A (zh) * 2014-04-01 2017-02-22 拜恩科技细胞&基因治疗有限公司 密封蛋白‑6特异性免疫受体和t细胞表位
US9718886B2 (en) 2010-07-06 2017-08-01 Ganymed Pharmaceuticals Ag Cancer therapy using CLDN6 target-directed antibodies in vivo
US9809815B2 (en) 2009-02-20 2017-11-07 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
WO2018105560A1 (ja) * 2016-12-07 2018-06-14 国立大学法人大阪大学 Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
WO2018207638A1 (ja) * 2017-05-08 2018-11-15 国立大学法人大阪大学 抗ｃｌｄｎ－５抗体、及びその抗体を含有する医薬
US10604568B2 (en) 2013-07-31 2020-03-31 BioN Tech AG Diagnosis and therapy of cancer involving cancer stem cells
JPWO2024085166A1 (ja) * 2022-10-19 2024-04-25
US12227586B2 (en) 2021-04-22 2025-02-18 Astellas Pharma Inc. Anti-CLDN4/anti-CD137 bispecific antibody

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
JP5043008B2 (ja) 2006-06-08 2012-10-10 中外製薬株式会社 炎症性疾患の予防または治療剤
CN101874041B (zh) 2007-09-26 2013-06-19 中外制药株式会社 抗体恒定区修饰体
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI548418B (zh) * 2007-12-05 2016-09-11 Chugai Pharmaceutical Co Ltd Anti-NR10 / IL-31RA antibody and its use
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
EP3674317B1 (en) 2009-03-19 2024-12-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CN102740877B (zh) * 2009-09-06 2015-01-14 普罗塔布有限公司 对源自hsp65的肽-6有特异性的人源化抗体及其方法和用途
JP6281163B2 (ja) 2011-08-22 2018-02-21 エメルゲント バイオソリューションズ カナダ クロストリジウム・ディフィシレ抗体
SG11201603397QA (en) 2013-11-06 2016-05-30 Stemcentrx Inc Novel anti-claudin antibodies and methods of use
HUE072989T2 (hu) 2015-04-14 2025-12-28 Chugai Pharmaceutical Co Ltd Gyógyszerkészítmény atópiás dermatitis megelõzésére és/vagy kezelésére, mely hatóanyagként IL-31 antagonistát tartalmaz
AU2016248786B2 (en) 2015-04-14 2022-01-20 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing lL-31 antagonist as active ingredient
US12077565B2 (en) * 2019-10-19 2024-09-03 Enrique GAMERO-ESTEVEZ Claudin-targeting agents and uses thereof
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos
JP2025527491A (ja) 2022-08-15 2025-08-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｃｌｄｎ４に対する抗体及びその使用方法
CN115851611B (zh) * 2022-10-26 2025-08-12 苏州仁端生物医药科技有限公司 一种分泌抗人Claudin 16蛋白单克隆抗体的杂交瘤细胞株及应用
CN116284400A (zh) * 2023-02-14 2023-06-23 襄阳市中心医院 Claudin4蛋白单克隆抗体的制备方法、免疫试纸条、试剂盒及其应用
WO2026002995A1 (en) 2024-06-24 2026-01-02 Avacta Life Sciences Limited Target-specific fap-activated topoisomerase inhibitor conjugates and uses thereof

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
JPS60221091A (ja) 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd 新規プロモ−タ−
JPS61178926A (ja) 1984-03-06 1986-08-11 Takeda Chem Ind Ltd 化学修飾ペプチドホルモンおよびその製造法
JPS63299A (ja) 1986-04-22 1988-01-05 イミユネツクス・コ−ポレ−シヨン ヒトｇ−ｃｓｆタンパク質の発現
JPH02117920A (ja) 1988-05-06 1990-05-02 Sumitomo Pharmaceut Co Ltd ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US4939094A (en) 1985-08-28 1990-07-03 Kyowa Hakko Kogyo Co., Ltd. Fused antigen polypeptide
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
WO1994023021A1 (fr) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
WO1997010354A1 (fr) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
JP3428441B2 (ja) 1998-05-15 2003-07-22 エーザイ株式会社 タイトジャンクション構成膜蛋白質クローディンファミリー
US20040091480A1 (en) 1996-04-03 2004-05-13 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
WO2005121338A1 (ja) 2004-06-07 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. 抗ｐｅｒｐ抗体
JP2006525351A (ja) * 2003-04-30 2006-11-09 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド ガンを診断および治療するための方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6830894B1 (en) 1998-11-03 2004-12-14 Adherex Technologies, Inc. Compounds and methods for modulating claudin-mediated functions
WO2003069307A2 (en) 2002-02-14 2003-08-21 The Johns Hopkins University School Of Medicine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
WO2006044335A2 (en) * 2004-10-14 2006-04-27 The Board Of Trustees Of The University Of Arkansas Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer
AU2007332473B2 (en) * 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
US4686191A (en) 1981-12-25 1987-08-11 Hakko Kogyo Co., Ltd. Kyowa Recombinant plasmid containing human interferon-beta gene
JPS60221091A (ja) 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd 新規プロモ−タ−
JPS61178926A (ja) 1984-03-06 1986-08-11 Takeda Chem Ind Ltd 化学修飾ペプチドホルモンおよびその製造法
US4939094A (en) 1985-08-28 1990-07-03 Kyowa Hakko Kogyo Co., Ltd. Fused antigen polypeptide
JPS63299A (ja) 1986-04-22 1988-01-05 イミユネツクス・コ−ポレ−シヨン ヒトｇ−ｃｓｆタンパク質の発現
JPH02117920A (ja) 1988-05-06 1990-05-02 Sumitomo Pharmaceut Co Ltd ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
US5160735A (en) 1989-06-19 1992-11-03 Kyowa Hakko Kogyo Co. Ltd. Plasminogen activator
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
WO1994023021A1 (fr) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
WO1997010354A1 (fr) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
US20040091480A1 (en) 1996-04-03 2004-05-13 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
JP3428441B2 (ja) 1998-05-15 2003-07-22 エーザイ株式会社 タイトジャンクション構成膜蛋白質クローディンファミリー
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
JP2006525351A (ja) * 2003-04-30 2006-11-09 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド ガンを診断および治療するための方法
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
WO2005121338A1 (ja) 2004-06-07 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. 抗ｐｅｒｐ抗体

Non-Patent Citations (145)

* Cited by examiner, † Cited by third party
Title
"Antibodies-A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
"Antibodies-A Laboratory Manual", 1988, SPRING HARBOR LABORATORY
"Antibody Engineering, A Practical Guide", 1992, W.H. FREEMAN AND COMPANY
"Bioconjugate Drug", 1993, HIROKAWA SHOTEN
"Bioluminescence and Chemical Luminescence", vol. 42, 1998, HIROKAWA SHOTEN
"Current Protocols in Molecular Biology"
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS
"DNA Cloning 1: Core Techniques, A Practical Approach", 1995, OXFORD UNIVERSITY
"Handbook of Clinical Test Methods", vol. 499, 1988, KANEHARA SHUPPAN
"Manual for Experiments of Monoclonal Antibodies", 1987, KODANSHA SCIENTIFIC
"Manual for Monoclonal Antibody Experiments", 1987, KODANSHA SCIENTIFIC
"Methods in Nucleic Acids Res.", vol. 283, 1991, CRC PRESS
"Molecular & General Genetics", vol. 168, 1979, pages: 111
"Molecular Cloning"
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LAB. PRESS
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
"Monoclonal Antibodies - Principles and practice", 1996, ACADEMIC PRESS
"Monoclonal Antibodies-Principles and practice", 1996, ACADEMIC PRESS
"Monoclonal Antibodies-Principles and Practice", 1996, ACADEMIC PRESS LIMITED
"Monoclonal Antibody Experiment Manual", 1987, KODANSHA SCIENTIFIC
"National Institute of Advanced Industrial Science and Technology", 31 July 2007, article "International Patent Organism Depositary"
"Sequence of Proteins of Immunological Interest", 1991, HEALTH AND HUMAN SERVICES
"SEQUENCES of Proteins of Immunological Interest", 1991, HEALTH
"SEQUENCES of Proteins of Immunological Interest", 1991, HEALTH AND HUMAN SERVICES
AGRIC. BIOL. CHEM., vol. 53, 1989, pages 1095
AGRIC. BIOL. CHEM., vol. 53, 1989, pages 277
AGRICULTURAL BIOLOGICAL CHEMISTRY, vol. 48, 1984, pages 669
AM. J. CLIN. PATHOL., vol. 121, 2004, pages 226
AM. J. PATHOL., vol. 164, 2004, pages 1627
AM. J. PATHOL., vol. 164, 2004, pages 903
APPL. IMMUNOHISTOCHEM. MOL. MORPHO., vol. 14, 2006, pages 24
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 149, 1987, pages 960
BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1
BIOLTECHNOLOGY, vol. 2, 1991, pages 266
BIOLTECHNOLOGY, vol. 9, 1991, pages 266
BLOOD, vol. 65, 1985, pages 1349
BR. J. CANCER, vol. 92, 2005, pages 1561
CANCER EPIDEMIOL. BIOMARKERS PREV., vol. 15, 2006, pages 281
CANCER IMMUNOL. IMMUNOTHER., vol. 36, 1993, pages 373
CANCER IMMUNOL. IMMUNOTHER., vol. 54, 2005, pages 431 - 445
CANCER RES., vol. 46, 1986, pages 6489
CANCER RES., vol. 52, 1992, pages 3402
CANCER RES., vol. 56, 1996, pages 1118
CANCER RES., vol. 61, 2001, pages 7878
CANCER RES., vol. 63, 2003, pages 6265
CANCER RES., vol. 65, 2005, pages 1868
CANCER RES., vol. 65, 2005, pages 4334
CANCER RES., vol. 65, 2005, pages 7378
CELL, vol. 33, 1983, pages 717
CELL, vol. 41, 1985, pages 479
CELL. BIOL., vol. 147, 1999, pages 195
CLIN. CANCER RES., vol. 10, 2004, pages 3291
CLIN. CANCER RES., vol. 10, 2004, pages 4427
CLIN. CANCER RES., vol. 9, 2003, pages 2567
COHEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 69, 1972, pages 2100
CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, pages 1 - 34
CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 18, 1978, pages 1 - 7
CYTOTECHNOL., vol. 1, 1990, pages 133
CYTOTECHNOL., vol. 13, 1993, pages 79
CYTOTECHNOL., vol. 4, 1990, pages 173
CYTOTECHNOLOGY, vol. 3, 1990, pages 133
DNA CLONING: A PRACTICAL APPROACH, vol. I, 1985, pages 49
EUROPEAN J. IMMUNOLOGY, vol. 6, 1976, pages 511 - 519
FEBS LETT., vol. 579, 2005, pages 6179
GASTROENTEROLOGY, vol. 121, 2001, pages 678
GENE, vol. 17, 1982, pages 107
GENE, vol. 27, 1984, pages 223
GENE, vol. 33, 1985, pages 103
GENE, vol. 34, 1985, pages 315
GENE, vol. 38, 1985, pages 275
GENES DEVELOP., vol. 4, 1990, pages 1288
GENETICS, vol. 39, 1954, pages 440
GENOME RES., vol. 7, 1997, pages 649
HUM. PATHOL., vol. 36, 2005, pages 886
HUM. PATHOL., vol. 38, 2007, pages 564
HYBRIDOMA, vol. 17, 1998, pages 559
IMMUNOL., vol. 85, 1995, pages 668
J. 1MMUNOL., vol. 144, 1990, pages 1382
J. BACTERIOL., vol. 172, 1990, pages 2392
J. BIOCHEM., vol. 101, 1987, pages 1307
J. BIOCHEMISTRY, vol. 101, 1987, pages 1307
J. BIOL. CHEM., vol. 271, 1996, pages 2966
J. BIOL. CHEM., vol. 272, 1997, pages 26652
J. CELL BIOL., vol. 136, 1997, pages 1239
J. CELL BIOL., vol. 147, 1999, pages 195
J. CELL. BIOL., vol. 147, 1999, pages 195
J. CLIN. ONCOL., vol. 2, 1984, pages 881
J. EXP. MED., vol. 115, 1962, pages 453
J. IMMUNOL. METHODS, vol. 167, 1994, pages 271
J. IMMUNOL., vol. 135, 1985, pages 1530
J. IMMUNOLOGY, vol. 123, 1979, pages 1548 - 1550
J. MOL. BIOL., vol. 112, 1977, pages 535
J. MOL. BIOL., vol. 16, 1966, pages 118
J. MOL. BIOL., vol. 166, 1983, pages 1
J. MOL. BIOL., vol. 215, 1990, pages 403
J. NATL. CANCER INST., vol. 80, 1988, pages 932
J. NATL. CANCER INST., vol. 80, 1988, pages 937
J. NUCL. MED., vol. 26, 1985, pages 1011
LOWE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 8227
METHODS IN ENZYMOL., vol. 154, 1987, pages 3
METHODS. MOL. BIOL., vol. 96, 1999, pages 177
MOD. PATHOL., vol. 19, 2006, pages 460
MOL. CELL. BIOL., vol. 3, 1983, pages 280
MOLECULAR IMMUNOL., vol. 32, 1995, pages 249
NAT. REV. MOL. CELL BIOL., vol. 2, 2001, pages 285
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, 31 July 2007 (2007-07-31)
NATL. ACAD. SCI. USA, vol. 78, 1981, pages 1527
NATL. REV. MOL. CELL BIOL., vol. 2, 2001, pages 285
NATURE BIOTECHNOL., vol. 15, 1997, pages 629
NATURE, vol. 227, 1970, pages 680
NATURE, vol. 256, 1975, pages 495 - 497
NATURE, vol. 276, 1978, pages 269 - 270
NATURE, vol. 322, 1988, pages 323
NATURE, vol. 329, 1987, pages 840
NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389
NUCLEIC ACIDS RESEARCH, vol. 10, 1982, pages 6487
NUCLEIC ACIDS RESEARCH, vol. 13, 1985, pages 4431
NUCLEIC ACIDS RESEARCH, vol. 17, 1989, pages 9494
OFFNER S. ET AL: "Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy", CANCER IMMUNOL. IMMUNOTHER., vol. 54, no. 5, 2005, pages 431 - 445, XP019333121 *
ONCOGENE, vol. 13, 2006, pages 2328
OSAMU KANEMITSU: "Antibody Engineering Handbook", 1994, CHIJIN SHOKAN
PAULSON ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 17619
PROC. NATL. ACAD. SCI. U.S.A., vol. 77, 1980, pages 4216
PROC. NATL. ACAD. SCI. USA, vol. 69, 1972, pages 2110
PROC. NATL. ACAD. SCI. USA, vol. 72, 1975, pages 4435
PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6409
PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 1242
PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 4306
PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488
PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413
PROTEIN ENGINEERING, Z, 1994, pages 1501
REITER ET AL., PROTEIN ENGINEERING, vol. 7, 1994, pages 697
SANGER, F. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 74, 1977, pages 5463
SCIENCE, vol. 122, 1952, pages 501
SCIENCE, vol. 222, 1983, pages 778
SCIENCE, vol. 242, 1988, pages 423
See also references of EP2138576A4
SOMATIC CELL AND MOLECULAR GENETICS, vol. 12, 1986, pages 55
SOMATIC CELL AND MOLECULAR GENETICS, vol. 12, 1986, pages 555
STRATEGIES, vol. 5, 1992, pages 58
STRATEGIES, vol. 5, 1992, pages 81
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519
VIRCHOWS ARCH., vol. 448, 2006, pages 52
VIROLOGY, vol. 8, 1959, pages 396
YAKUGAKU ZASSHI, vol. 126, 2006, pages 711

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809815B2 (en) 2009-02-20 2017-11-07 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
US11473085B2 (en) 2009-02-20 2022-10-18 Ganymed Pharmaceuticals Gmbh Methods and compositions for diagnosis and treatment of cancer
US11858988B2 (en) 2009-11-11 2024-01-02 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (CLDN6)
US10745477B2 (en) 2009-11-11 2020-08-18 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (CLDN6)
US9487584B2 (en) 2009-11-11 2016-11-08 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
US9932401B2 (en) 2009-11-11 2018-04-03 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
US9902778B2 (en) 2010-07-06 2018-02-27 Ganymed Pharmaceuticals Ag Cancer therapy using CLDN6 target-directed antibodies in vivo
US10844133B2 (en) 2010-07-06 2020-11-24 Ganymed Pharmaceuticals Gmbh Cancer therapy using CLDN6 target-directed antibodies in vivo
US9718886B2 (en) 2010-07-06 2017-08-01 Ganymed Pharmaceuticals Ag Cancer therapy using CLDN6 target-directed antibodies in vivo
US11859008B2 (en) 2011-05-13 2024-01-02 Ganymed Pharmaceuticals Gmbh Antibodies for treatment of cancer expressing claudin 6
US10233253B2 (en) 2011-05-13 2019-03-19 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US10919974B2 (en) 2011-05-13 2021-02-16 Ganymed Pharmaceuticals Gmbh Antibodies for treatment of cancer expressing claudin 6
US9321842B2 (en) 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
JP2018090608A (ja) * 2013-03-01 2018-06-14 公益財団法人ヒューマンサイエンス振興財団 抗体
WO2014132647A1 (ja) * 2013-03-01 2014-09-04 公益財団法人ヒューマンサイエンス振興財団 抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー
JP2014193853A (ja) * 2013-03-01 2014-10-09 Japan Health Sciences Foundation 抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー
US11795218B2 (en) 2013-07-31 2023-10-24 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
US10604568B2 (en) 2013-07-31 2020-03-31 BioN Tech AG Diagnosis and therapy of cancer involving cancer stem cells
CN113150109A (zh) * 2014-04-01 2021-07-23 拜恩科技细胞&基因治疗有限公司 密封蛋白-6特异性免疫受体和t细胞表位
CN106459165A (zh) * 2014-04-01 2017-02-22 拜恩科技细胞&基因治疗有限公司 密封蛋白‑6特异性免疫受体和t细胞表位
JPWO2018105560A1 (ja) * 2016-12-07 2019-10-24 国立大学法人大阪大学 Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
WO2018105560A1 (ja) * 2016-12-07 2018-06-14 国立大学法人大阪大学 Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
US10882906B2 (en) 2016-12-07 2021-01-05 Osaka University Claudin 5 antibody, and medicine containing said antibody
JP7108956B2 (ja) 2017-05-08 2022-07-29 国立大学法人大阪大学 抗ｃｌｄｎ－５抗体、及びその抗体を含有する医薬
JPWO2018207638A1 (ja) * 2017-05-08 2020-03-12 国立大学法人大阪大学 抗ｃｌｄｎ−５抗体、及びその抗体を含有する医薬
US11053313B2 (en) 2017-05-08 2021-07-06 Osaka University Anti-CLDN-5 antibody, and drug containing said antibody
WO2018207638A1 (ja) * 2017-05-08 2018-11-15 国立大学法人大阪大学 抗ｃｌｄｎ－５抗体、及びその抗体を含有する医薬
US12227586B2 (en) 2021-04-22 2025-02-18 Astellas Pharma Inc. Anti-CLDN4/anti-CD137 bispecific antibody
EP4327823A4 (en) * 2021-04-22 2025-04-30 Astellas Pharma Inc. BISPECIFIC ANTI-CLDN4/ANTI-CD137 ANTIBODY
JPWO2024085166A1 (ja) * 2022-10-19 2024-04-25
WO2024085166A1 (ja) * 2022-10-19 2024-04-25 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
KR20250089513A (ko) 2022-10-19 2025-06-18 아스텔라스세이야쿠 가부시키가이샤 암 치료에 있어서의 pd-1 시그널 저해제와의 조합에 의한 항cldn4-항cd137 이중특이성 항체의 사용
JP7730432B2 (ja) 2022-10-19 2025-08-27 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用

Also Published As

Publication number Publication date
EP2138576A1 (en) 2009-12-30
JPWO2008114733A1 (ja) 2010-07-01
US20090202556A1 (en) 2009-08-13
EP2138576A4 (en) 2011-02-23
US8076458B2 (en) 2011-12-13

Similar Documents

Publication Publication Date Title
WO2008114733A1 (ja) 抗Claudin-4抗体
WO2009028663A1 (ja) 抗Claudin-3抗体
JP2020511152A5 (ja)
JP2016511277A5 (ja)
JP2008520186A5 (ja)
JP2016537966A5 (ja)
WO2010021697A3 (en) Antibodies to ccr2
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
CA2699834A1 (en) Improved anti-il-6 receptor antibody
NO20090406L (no) Antigen-bindende molekyler som binder EGFR, vektorer som koder for disse og anvendelser derav
JP2010511388A5 (ja)
WO2010037838A3 (en) Cross-species-specific single domain bispecific single chain antibody
RU2012112340A (ru) Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
JP2017508466A5 (ja)
WO2008031133A3 (en) Borrelia antigens
MX363905B (es) Proteinas de union multivalentes monocatenarias con funcion efectora.
JP2013502204A5 (ja)
JP2015525211A5 (ja)
UA92580C2 (ru) Антитело, которое специфически связывается с cd22, и его терапевтическое и диагностическое применение
FI3137504T3 (fi) Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten
HRP20192134T1 (hr) Molekule za vezanje na antigen koji veže egfr, vektori koji ih kodiraju, te njihove primjene
JP2016524463A5 (ja)
FI3309176T3 (fi) Immunoglobuliinin yksittäinen vaihteleva domeeni -vasta-aineita ox40l:ää vastaan, konstrukteja ja niiden terapeuttinen käyttö
WO2008054603A3 (en) Il-17 receptor a antigen binding proteins
AU2011262758A8 (en) Anti-tim-3 antibody

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08722165

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009505202

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008722165

Country of ref document: EP